Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Drug Alcohol Depend. 2012 Feb 23;124(3):268–273. doi: 10.1016/j.drugalcdep.2012.01.019

Table 3.

Model results of the association of ADHD symptoms score with treatment, nicotine withdrawal symptoms, craving to smoke and abstinence status after target quit date (weeks 2, 4 and 6 post-quit).



Basic
modela
Basic model
plus
withdrawal		 Basic model
plus interaction
OROS-MPH
(vs.placebo)
and withdrawal		 Basic
model
plus
craving		 Basic model
plus interaction
OROS-MPH
(vs.placebo)
and craving
β (s.e.)
Abstinence 0.28
(0.72)		 0.41
(0.71)		 0.42
(0.71)		 0.14
(0.76)		 0.13
(0.76)
OROS-MPH (vs.
placebo)		 −6.05 **
(1.38)		 −4.50 *
(1.26)		 −7.36 **
(1.65)		 −5.98 **
(1.36)		 −5.40*
(1.76)
Withdrawal symptoms 0.55 **
(0.07)		 0.38 **
(0.09)
Interaction between
OROS-MPH (vs.
placebo) and withdrawal		 0.35 *
(0.13)
Craving 0.35
(0.30)		 0.50
(0.41)
Interaction between
OROS-MPH (vs.
placebo) and craving		 −0.30
(0.58)
*

p<0.001,

**

p<0.0001

a.

Adjusted for age, gender, race, treatment, week of assessment, site, nicotine patch compliance, osmotic-release oral system methylphenidate (OROS-MPH) vs. placebo compliance, and baseline ADHD score.

ADHD: attention-deficit/hyperactivity disorder